Portola Pharmaceuticals (PTLA) Holder Hartwell J M Limited Partnership Has Cut Its Holding; Frontfour Capital Group Has Raised Centurylink (Call) (CTL) Stake

April 25, 2018 - By Nellie Frank

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Logo

Frontfour Capital Group Llc increased its stake in Centurylink Inc (Call) (CTL) by 40.72% based on its latest 2017Q4 regulatory filing with the SEC. Frontfour Capital Group Llc bought 44,100 shares as the company’s stock declined 6.44% with the market. The hedge fund held 152,400 shares of the public utilities company at the end of 2017Q4, valued at $2.54M, up from 108,300 at the end of the previous reported quarter. Frontfour Capital Group Llc who had been investing in Centurylink Inc (Call) for a number of months, seems to be bullish on the $19.37 billion market cap company. The stock increased 0.11% or $0.02 during the last trading session, reaching $17.95. About 1.96 million shares traded. CenturyLink, Inc. (NYSE:CTL) has declined 28.66% since April 25, 2017 and is downtrending. It has underperformed by 40.21% the S&P500.

Hartwell J M Limited Partnership decreased its stake in Portola Pharmaceuticals (PTLA) by 17.84% based on its latest 2017Q4 regulatory filing with the SEC. Hartwell J M Limited Partnership sold 6,325 shares as the company’s stock declined 43.57% with the market. The hedge fund held 29,125 shares of the health care company at the end of 2017Q4, valued at $1.42 million, down from 35,450 at the end of the previous reported quarter. Hartwell J M Limited Partnership who had been investing in Portola Pharmaceuticals for a number of months, seems to be less bullish one the $2.24B market cap company. The stock decreased 1.50% or $0.52 during the last trading session, reaching $34.09. About 241,438 shares traded. Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) has declined 20.86% since April 25, 2017 and is downtrending. It has underperformed by 32.41% the S&P500.

Since April 3, 2018, it had 2 buys, and 0 sales for $215.07 million activity.

Frontfour Capital Group Llc, which manages about $447.90M and $370.25 million US Long portfolio, decreased its stake in Altaba Inc by 102,994 shares to 40,662 shares, valued at $2.84M in 2017Q4, according to the filing. It also reduced its holding in Spdr S&P 500 Etf Tr (Put) (SPY) by 345,600 shares in the quarter, leaving it with 294,200 shares, and cut its stake in Hain Celestial Group Inc (NASDAQ:HAIN).

Investors sentiment increased to 1.99 in Q4 2017. Its up 1.04, from 0.95 in 2017Q3. It is positive, as 78 investors sold CTL shares while 110 reduced holdings. 118 funds opened positions while 256 raised stakes. 888.76 million shares or 103.84% more from 436.00 million shares in 2017Q3 were reported. Pictet Asset Mgmt has invested 0.02% in CenturyLink, Inc. (NYSE:CTL). Fukoku Mutual Life Co invested 0.01% in CenturyLink, Inc. (NYSE:CTL). Us Natl Bank De reported 997,505 shares stake. 910 are held by Hanson Mcclain. American Research & Mngmt reported 1,084 shares. Hartford Financial invested in 62 shares or 0% of the stock. Reaves W H invested 1.64% in CenturyLink, Inc. (NYSE:CTL). Auxier Asset Mgmt stated it has 0.18% of its portfolio in CenturyLink, Inc. (NYSE:CTL). Earnest Prns Ltd Company holds 505 shares or 0% of its portfolio. Clark Estates Inc Ny owns 1.20M shares for 3.31% of their portfolio. Mark Sheptoff Finance Planning Ltd Com holds 0.01% or 500 shares. Endurance Wealth Management invested in 4,175 shares or 0.01% of the stock. Jpmorgan Chase Communications holds 0.02% or 6.16 million shares in its portfolio. Geode Capital Limited Liability Company, a Massachusetts-based fund reported 10.37 million shares. Moreover, Daiwa Securities Group has 0% invested in CenturyLink, Inc. (NYSE:CTL).

Among 23 analysts covering Centurylink Inc. (NYSE:CTL), 7 have Buy rating, 1 Sell and 15 Hold. Therefore 30% are positive. Centurylink Inc. had 60 analyst reports since July 31, 2015 according to SRatingsIntel. The firm has “Buy” rating by UBS given on Thursday, November 9. As per Monday, May 15, the company rating was downgraded by Raymond James. Jefferies maintained CenturyLink, Inc. (NYSE:CTL) on Tuesday, October 3 with “Hold” rating. The firm has “Hold” rating given on Thursday, February 15 by Cowen & Co. The firm earned “Underperform” rating on Thursday, March 17 by Jefferies. The rating was maintained by Deutsche Bank on Tuesday, October 10 with “Hold”. The firm has “Sector Perform” rating given on Tuesday, September 22 by RBC Capital Markets. The rating was initiated by Suntrust Robinson with “Hold” on Tuesday, December 13. Barclays Capital initiated CenturyLink, Inc. (NYSE:CTL) rating on Tuesday, September 15. Barclays Capital has “Underweight” rating and $25 target. Barclays Capital maintained it with “Underweight” rating and $19 target in Wednesday, October 4 report.

Hartwell J M Limited Partnership, which manages about $535.54 million and $532.32M US Long portfolio, upped its stake in Alibaba Group (NYSE:BABA) by 27,680 shares to 131,925 shares, valued at $22.75M in 2017Q4, according to the filing. It also increased its holding in Citigroup Inc by 8,277 shares in the quarter, for a total of 13,277 shares, and has risen its stake in Vantiv Inc. (NYSE:VNTV).

Analysts await Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) to report earnings on May, 14. They expect $-1.46 EPS, down 97.30% or $0.72 from last year’s $-0.74 per share. After $-1.41 actual EPS reported by Portola Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 3.55% negative EPS growth.

Among 7 analysts covering Portola Pharmaceuticals (NASDAQ:PTLA), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Portola Pharmaceuticals had 39 analyst reports since August 5, 2015 according to SRatingsIntel. The rating was maintained by Oppenheimer with “Buy” on Monday, January 15. The rating was maintained by Oppenheimer with “Buy” on Thursday, December 28. The firm has “Buy” rating given on Wednesday, August 9 by Cowen & Co. Credit Suisse maintained the stock with “Outperform” rating in Monday, March 28 report. The stock of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) earned “Buy” rating by Morgan Stanley on Monday, June 26. The stock of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) has “Buy” rating given on Wednesday, August 10 by Citigroup. The stock has “Buy” rating by Credit Suisse on Wednesday, September 20. The stock of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) earned “Buy” rating by Cowen & Co on Monday, June 26. Oppenheimer maintained the stock with “Buy” rating in Monday, June 26 report. The firm has “Outperform” rating by Credit Suisse given on Wednesday, February 21.

Investors sentiment decreased to 1.36 in 2017 Q4. Its down 0.80, from 2.16 in 2017Q3. It turned negative, as 32 investors sold PTLA shares while 45 reduced holdings. 30 funds opened positions while 75 raised stakes. 56.35 million shares or 0.04% more from 56.33 million shares in 2017Q3 were reported. Fortaleza Asset reported 1,725 shares. Moreover, Geode Mngmt Ltd has 0.01% invested in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) for 620,913 shares. Temasek (Private) Limited accumulated 4.88M shares. 378,006 were accumulated by Comml Bank Of New York Mellon. Assetmark owns 6 shares. Moreover, Creative Planning has 0.01% invested in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) for 39,266 shares. Cadian Limited Partnership, New York-based fund reported 1.52 million shares. Parallax Volatility Advisers Lp reported 0% of its portfolio in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Smith Asset Gru Ltd Partnership reported 9,460 shares or 0.01% of all its holdings. Ghost Tree Ltd Liability Company holds 2.57% or 225,000 shares. Jpmorgan Chase & has 650,264 shares. 734,070 are held by Northern Trust Corporation. Sei Investments has invested 0% in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Susquehanna Group Limited Liability Partnership invested 0.01% in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Texas-based Highland Cap Lp has invested 0.99% in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA).

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>